UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children

Study will focus on group childcare and early childhood education settings located in Worcester and Cambridge to understand transmission and support prevention of CMV

WORCESTER, Mass., March 22, 2022 /PRNewswire/ -- UMass Chan Medical School today announced a research collaboration with Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)-based therapeutics and vaccines, on a comprehensive study of cytomegalovirus (CMV) transmission in group childcare, education, and household settings.

More than half of people in the U.S. will be infected with CMV by the age of 40. The vast majority of adults experience very mild or no symptoms with their initial (primary) CMV infection. Young children with CMV infection can shed the virus in their saliva or urine over months to years, making transmission of the virus very easy in group daycare, early education, or household settings where playing, sharing toys, eating, and diaper changes are daily opportunities for infection. Studying the patterns of transmission and immune responses that control spread in these settings could support development of a CMV vaccine intended to prevent CMV infection.

The study, called CMV Transmission and Immune Tracking (CMV TransmIT), will examine how CMV spreads among children and between household members, with an aim to characterize immune responses to CMV infection over time. Findings from the study will inform the design of CMV prevention strategies, including awareness campaigns for CMV, to reduce its spread in similar group settings.

The study will be led by Laura Gibson, MD, an Adult and Pediatric Infectious Disease specialist at UMass Chan. Dr. Gibson has extensive expertise in congenital CMV infection, including studies of T cell responses to CMV in children.

"Human cytomegalovirus is the most common infection acquired before birth, affecting approximately one of every 200 live-born infants every year," said Dr. Gibson. "Current strategies for effective prevention or treatment of CMV are extremely limited. We hope that this study will generate new evidence to help us understand how the immune systems of young children and adults control and reduce the spread of CMV, which could guide the design of a vaccine to generate those effective immune responses."

CMV is the most common infectious cause of birth defects in the world. The virus can spread from pregnant women to their unborn children, a condition known as congenital CMV infection (cCMV).  Infants with cCMV at birth are at risk for abnormal neurodevelopment, including hearing loss and microcephaly.  Overall, nearly 20% of infants with cCMV have long term effects from the virus.

"CMV is a complex virus and preventing the range of complications from congenital CMV infection is a significant unmet medical need," said Lori Panther, MD, MPH, VP, Clinical Development, Infectious Diseases, Moderna. "There is currently no approved vaccine against CMV infection, which impacts the lives of so many. As we work to advance the science of CMV prevention, we are encouraged that Dr. Gibson's study will contribute to our understanding of CMV transmission dynamics and the immune response to CMV infection in this population.   We are hopeful that Moderna will be able to look to these results to inform the development of a safe and effective vaccine against CMV infection."

"We are working to build a network of public and private licensed daycare centers in Cambridge and Worcester to identify CMV positive children who are transmitting the virus and CMV negative children who are at risk for acquiring the infection," added Dr. Gibson. "Worcester and Cambridge were identified as communities for the study due to the locations of UMass Chan and Moderna, respectively, as well as the diverse populations within these cities."

Enrollment in the study is likely to begin in fall 2022. For more information about CMV, visit https://www.nationalcmv.org or www.nowiknowcmv.com.

About UMass Chan Medical School
The UMass Chan Medical School, one of five campuses of the University of Massachusetts system, comprises the T.H. Chan School of Medicine, the Morningside Graduate School of Biomedical Sciences, the Tan Chingfen Graduate School of Nursing; a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. UMass Chan's mission is to advance the health and wellness of our diverse communities throughout Massachusetts and across the world by leading and innovating in education, research, health care delivery and public service. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education, perennially ranked in the top 10 percent of medical schools for primary care by U.S. News and World Report. UMass Chan attracts more than $400 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2021, the Medical School received a $175 million donation from The Morningside Foundation and was renamed the UMass Chan Medical School.

SOURCE UMass Chan Medical School